Merck lung cancer drug Keytruda plus chemo gets FDA approval for NSCLC

Merck’s cancer immunotherapy Keytruda (pembrolizumab) in combination with chemotherapy has been approved by the US Food and Drug Administration (FDA) as a first-line option for advanced lung cancer treatment in patients who didn’t take any medicines before for the disease.

Merck lung cancer drug Keytruda plus chemo gets FDA approval for NSCLC

Merck’s cancer immunotherapy Keytruda (pembrolizumab) in combination with chemotherapy has been approved by the US Food and Drug Administration (FDA) as a first-line option for advanced lung cancer treatment in patients who didn’t take any medicines before for the disease. The Keytruda chemotherapy combination has been approved to treat metastatic non-squamous non small cell lung […]

Genetech’s lucentis approved by US FDA for diabetic retinopathy treatment

The US FDA has approved lucentis (ranibizumab injection) for diabetic retinopathy treatment. Read the Lucentis FDA approval story in our pharma news updates section at DailyHealthNeeds.com.

Genetech’s lucentis approved by US FDA for diabetic retinopathy treatment

Genentech’s injection to treat diabetic retinopathy, lucentis (ranibizumab injection) has been approved by the U.S. Food and Drug Administration (FDA). The approved dosage of ranibizumab injection to be administered monthly once is 0.3mg for treating all types of diabetic retinopathy. Diabetic Retinopathy Treatment with Lucentis Injection Lucentis FDA approval means that the drug is now […]

APAC Biotech’s Immuno-oncology drug Apceden gets approved in India

The Indian FDA (CDSCO - Central Drugs Standard Control Organization) has granted a commercial license to APAC Biotech to market Apceden, a Dendritic cell-based autologous Immuno-oncology drug for prostate, ovarian, colo-rectal and non small cell lung carcinoma form of cancers.

APAC Biotech’s Immuno-oncology drug Apceden gets approved in India

The Indian FDA (CDSCO – Central Drugs Standard Control Organization) has granted a commercial license to APAC Biotech to market Apceden, a Dendritic cell-based autologous Immuno-oncology drug for prostate, ovarian, colo-rectal and non small cell lung carcinoma form of cancers. Following a stringent review of the application submitted by the Indian biotechnology company, the Indian […]

Neurocrine’s Ingrezza approved by FDA for tardive dyskinesia treatment

The US Food and Drug Administration (FDA) has approved for Ingrezza (valbenazine) capsules developed by Neurocrine Biosciences for the treatment of tardive dyskinesia patients.

Neurocrine’s Ingrezza approved by FDA for tardive dyskinesia treatment

The US Food and Drug Administration (FDA) has approved for Ingrezza (valbenazine) capsules developed by Neurocrine Biosciences for the treatment of tardive dyskinesia patients. A selective vesicular monoamine transporter 2 (VMAT2) inhibitor, Ingrezza has become the first drug to be approved by the regulator to treat adults suffering from tardive dyskinesia. VMAT2 is a protein […]

Genentech MS drug Ocrevus approved by FDA for multiple sclerosis treatment

Roche Group’s subsidiary Genentech has secured the US FDA approval for its multiple sclerosis drug, Ocrevus (ocrelizumab) for treating both relapsing and primary progressive variants of the chronic disease through intravenous infusion.

Genentech MS drug Ocrevus approved by FDA for multiple sclerosis treatment

Roche Group’s subsidiary Genentech has secured the US FDA approval for its multiple sclerosis drug, Ocrevus (ocrelizumab) for treating both relapsing and primary progressive variants of the chronic disease through intravenous infusion. The FDA approval has made the Genentech MS drug Ocrevus as the first and only therapy available for the two forms of multiple […]

Dupixent eczema injection gets FDA approval for atopic dermatitis treatment

Dupixent (dupilumab), the co-developed eczema injection from pharma giants Sanofi and Regeneron Pharmaceuticals, has got the US FDA approval for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients.

Dupixent eczema injection gets FDA approval for atopic dermatitis treatment

Dupixent (dupilumab), the co-developed eczema injection from pharma giants Sanofi and Regeneron Pharmaceuticals, has got the US FDA approval for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients. Dupixent eczema injection with that has become the first ever biologic medicine approved for atopic dermatitis treatment in patients whose disease is not managed adequately […]

Lilly’s breast cancer drug abemaciclib meets objective in phase 3 trial

Lilly’s breast cancer drug, abemaciclib given in combination with fulvestrant has met its primary endpoint of progression-free survival (PFS) in a phase 3 breast cancer trial.

Lilly’s breast cancer drug abemaciclib meets objective in phase 3 trial

Indianapolis-based Lilly has reported that its breast cancer drug, abemaciclib, in combination with fulvestrant, has yielded positive results by meeting its primary endpoint, progression-free survival (PFS) in a phase 3 breast cancer trial. The combination of Lilly breast cancer drug abemaciclib with fulvestrant was proved to be more effective than the fulvestrant plus placebo combination […]

New oral blood thinner rivaroxaban from Bayer and Jannsen shown to cut recurrence of life-threatening blood clots

Check out results of the late-breaking blood thinner clinical trial of Rivaroxaban, Bayer & Janssen’s oral blood thinner for deep vein thrombosis treatment.

New oral blood thinner rivaroxaban from Bayer and Jannsen shown to cut recurrence of life-threatening blood clots

Bayer and Janssen Pharmaceuticals have revealed that their jointly developed oral blood thinner Xarelto (rivaroxaban) had considerably brought down the risk of recurring formation of life-threatening blood clots in the vein as per the findings of their late-breaking study. Rivaroxaban Blood Thinner Clinical Trial This, they demonstrated in a blood thinner clinical trial dubbed EINSTEIN CHOICE. […]

Astrazeneca ovarian cancer drug Lynparza shown to improve survival chances

Check out details of Astrazeneca Ovarian Cancer Drug, Lynparza which in a phase 3 trial has been demonstrated to have improved survival of patients treated with Lynparza Ovarian Cancer Tablets.

Astrazeneca ovarian cancer drug Lynparza shown to improve survival chances

Pharma giant AstraZeneca has reported that its ovarian cancer drug Lynparza (olaparib) as a maintenance therapy has considerably improved the survival chances of patients with germline BRCA-mutations (gBRCA) who had a relapse of the disease, who did not respond to platinum-based chemo. Phase 3 Trial of Astrazeneca Ovarian Cancer Drug Lynparza The observation of the […]

1 2 3 5